Drugs / sulfahexafluoride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04663750 | Apr 2021 → Dec 2028 expected | wet macular degeneration | King's College Hospital NHS Trust | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sulfahexafluoride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04663750 ↗ |
| Known as | SF6 | “Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.” NCT04663750 ↗ |
| Route | Intravitreal | “Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.” NCT04663750 ↗ |